In February 2020 Novartis joined the Rare Disease Action Forum (RDAF) as member. With its members coming from industry, patient organizations, Healthcare Professionals and research organizations, the RDAF acts as multi-stakeholder platform in the field of rare diseases. With its increased membership the RDAF reinforces its contribution to improve access to diagnosis, treatment and patient care for patients with rare diseases in Switzerland.
Internationaler Tag der Seltenen Krankheiten 2026: Gemeinsam Fortschritte stärken und die Versorgung nachhaltig verbessern
Am heutigen Internationalen Tag der Seltenen Krankheiten erinnert das Rare Disease Action Forum (RDAF) daran, dass über 500'000 Menschen in der Schweiz von einer seltenen Erkrankung betroffen sind, viele von ihnen weiterhin ohne gesicherten Zugang zu Diagnose,...